Melatonin's role as a co-adjuvant treatment in colonic diseases: A review

Eduardo Esteban-Zubero, Laura López-Pingarrón, Moisés Alejandro Alatorre-Jiménez, Purificación Ochoa-Moneo, Celia Buisac-Ramón, Miguel Rivas-Jiménez, Silvia Castán-Ruiz, Ángel Antoñanzas-Lombarte, Dun-Xian Tan, José Joaquín García, Russel J. Reiter

PII: S0024-3205(16)30684-1
DOI: doi: 10.1016/j.lfs.2016.11.031
Reference: LFS 15097
To appear in: Life Sciences

Received date: 9 October 2016
Revised date: 17 November 2016
Accepted date: 30 November 2016

Please cite this article as: Eduardo Esteban-Zubero, Laura López-Pingarrón, Moisés Alejandro Alatorre-Jiménez, Purificación Ochoa-Moneo, Celia Buisac-Ramón, Miguel Rivas-Jiménez, Silvia Castán-Ruiz, Ángel Antoñanzas-Lombarte, Dun-Xian Tan, José Joaquín García, Russel J. Reiter, Melatonin's role as a co-adjuvant treatment in colonic diseases: A review. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Lfs(2016), doi: 10.1016/j.lfs.2016.11.031

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Melatonin’s role as a co-adjuvant treatment in colonic diseases: a review

Eduardo Esteban-Zubero\textsuperscript{a*}, Laura López-Pingarrón\textsuperscript{b}, Moisés Alejandro Alatorre-Jiménez\textsuperscript{c}, Purificación Ochoa-Moneo\textsuperscript{b}, Celia Buisac-Ramón\textsuperscript{d}, Miguel Rivas-Jiménez\textsuperscript{b}, Silvia Castán-Ruiz\textsuperscript{d}, Ángel Antoñanzas-Lombarte\textsuperscript{b}, Dun-Xian Tan\textsuperscript{c}, José Joaquín García\textsuperscript{a}, Russel J. Reiter\textsuperscript{c*}.

\textsuperscript{a} Department of Pharmacology and Physiology, University of Zaragoza. Calle Domingo Miral s/n, 50009. Zaragoza, Spain.

\textsuperscript{b} Department of Medicine, Psychiatry and Dermatology, University of Zaragoza. Calle Domingo Miral s/n, 50009. Zaragoza, Spain.

\textsuperscript{c} Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio. 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.

\textsuperscript{d} Primary Care Unit, Sector Zaragoza III, Avenida San Juan Bosco 5, 50009. Zaragoza, Spain.

Running title: Melatonin and gastrointestinal diseases

* Authors to whom correspondence should be addressed; E-Mails: eezubero@gmail.com (E.E.Z.), reiter@uthscsa.edu (R.J.R.).

No conflict of interest shown in the realization of this writing and any comments are received. All authors agree with the work done and have collaborated actively in its development.

\textbf{Word count:} 4293

\textbf{Table and figure count:} 1 table, 2 figures
Abbreviations:

Melatonin receptors (MT2), serotonin (5-HT), and cholecystokinin B (CCK2), irritable bowel syndrome (IBS), constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), enterochromaffin cells (EC), gastrointestinal (GIT), nitric oxide synthase (NOS) nuclear factor kappaB (NF-κB), inducible NOS (iNOS), interleukins (IL), tumor necrosis factor alpha (TNF-α), reactive nitrogen species (RNS), superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione reductase (GRd), catalase (CAT), glutathione (GSH), corticotropin releasing factor (CRF), 6-Hydroxymelatonin sulphate (6-OHMs), Crohn’s disease (CD), ulcerative colitis (UC), colitis-associated colon carcinogenesis (CACC), Nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), quinone oxidoreductase (NQO-1), Kelch-like ECH-associated protein 1 (Keap1), hydroxyindole-O-methyltransferase (HIOMT), homocysteine (HCY), lipid peroxidation (LPO), myeloperoxidase activity (MPO), Melatonin (MEL), malondialdehyde (MDA), prostaglandin E2 (PGE2), matrix metallopeptidase (MMP), pentraxin-3 (PTX-3).

Author contributions:

Abstract: Melatonin is produced in the pineal gland as well as many other organs, including the enterochromaffin cells of the digestive mucosa. Melatonin is a powerful antioxidant that resists oxidative stress due to its capacity to directly scavenge reactive species, to modulate the antioxidant defense system by increasing the activities of antioxidant enzymes, and to stimulate the innate immune response through its direct and indirect actions. In addition, the dysregulation of the circadian system is observed to be related with alterations in colonic motility and cell disruptions due to the modifications of clock genes expression. In the gastrointestinal tract, the activities of melatonin are mediated by melatonin receptors (MT2), serotonin (5-HT), and cholecystokinin B (CCK2) receptors and via receptor-independent processes. The levels of melatonin in the gastrointestinal tract exceed by 10-100 times the blood concentrations. Also, there is an estimated 400 times more melatonin in the gut than in the pineal gland. Gut melatonin secretion is suggested to be influenced by the food intake. Low dose melatonin treatment accelerates intestinal transit time whereas high doses may decrease gut motility. Melatonin has been studied as a co-adjuvant treatment in several gastrointestinal diseases including irritable bowel syndrome (IBS), constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), Crohn’s disease, ulcerative colitis, and necrotizing enterocolitis. The purpose of this review is to provide information regarding the potential benefits of melatonin as a co-adjuvant treatment in gastrointestinal diseases, especially IBS, Crohn’s disease, ulcerative colitis, and necrotizing enterocolitis.

Keywords: Gastrointestinal diseases; Crohn’s disease; melatonin; ulcerative colitis; irritable bowel syndrome; necrotizing enterocolitis.
1. **Introduction:**

Gastrointestinal melatonin is produced by enterochromaffin cells (EC) of the digestive mucosa where its concentrations may exceed those in the blood [1]. One of melatonin’s characteristics is its high lipophilicity allowing it to diffuse into deeper layers through the mucosa and submucosa, to act on the muscularis mucosae or the myenteric plexus. The amount of gastrointestinal (GIT) melatonin is estimated to be at least 400 times greater than in the pineal gland [2]. Its secretion from the EC cells may be influenced by food intake [3], its actions in the GIT are mediated by membrane receptors including (MT2), serotonin (5-HT) receptors, and its capacity of activate sympathetic neurons through the brain-gut connection system, and its antioxidant actions [4-8]. Melatonin produces smooth muscle relaxation by stimulating 5-HT4 receptors, whereas it may also cause smooth muscle contraction by acting on 5-HT3 receptors. 5-HT also modulates visceral sensation [6, 9]. Moreover, it was observed recently that melatonin may inhibit the activity of the serotonin transporter, which controls the reuptake of 5-HT by intestinal epithelial cells, and inhibits NK2 receptor-triggered 5-HT release by acting at a MT3 melatonin receptor located in the cells of the mucosal layer [10]. Low dose melatonin is also observed to accelerate intestinal transit time while high doses may decrease GIT motility by interacting with cholecystokinin B receptor (CCK2) and 5-HT3 receptors, present on the vagal afferent fibers inducing, via this means, vago-vagal inhibitory reflexes [3, 4]. Those findings are supported by melatonin’s modulatory role on gastric emptying due to its capacity to alleviate the inhibitory effect of the lipid related ileal break [11].

Other roles related to motility regulation by melatonin have been suggested. The indoleamine reduces the nitrergic component of the smooth muscle inhibitory junction potential through a direct inhibition of nitric oxide synthase (NOS) activity at enteric synapses. Melatonin may also block nicotinic channels, or interact with Ca\(^{2+}\)-activated K\(^{+}\) channels generating an inhibitory effect through an apamin-sensitive reaction [12, 13]. Melatonin also modulates acetylcholine-induced contractions of intestinal strips by an extracellular calcium dependent pathway [14]. In addition, melatonin may reverse lipopolysaccharide-induced motility
disturbances, which involves a reduction in lipid peroxidation and an increase of mitogen-activated protein kinase activation, nuclear factor kappaB (NF-κB) activation, inducible NOS (iNOS) expression, and finally nitrite production [15]. Finally, melatonin regulates myoelectric activity by relaxing the bowel during phasic contractions [16].

Antinociceptive effects of melatonin have been reported, but the mechanisms are not well defined. A recent study suggested that these actions of melatonin were probably not directly at the level of the GIT since luzindole (a non-specific MT1 and MT2 receptor antagonist), or naltrexone (a non-specific opioid receptor antagonist), blocked the antinociceptive actions; this suggested visceromotor response and modulation of lumbosacral spinal neuronal activity [17].

Gastrointestinal melatonin may also modulate the immune response by inhibiting macrophage activity through the reduction of NF-κB levels, COX-2 and iNOS activity; also, it modulates secretion elicited by prostaglandin E2 and regulates gene expression of proinflammatory cytokine levels including interleukins (IL-1), tumor necrosis factor alpha (TNF-α) and IFN-γ [18, 21]. In addition, gastrointestinal melatonin has antioxidant effects [22, 23], reduces prostaglandin degradation by prostaglandin reductase and limits gastric lesions and hydrochloric acid secretion [22-24]; it also antagonizes 5-HT actions, which are related to gastric ulcer formation [3].

Melatonin and its metabolites function as free radical scavengers and neutralize superoxide (O$_2^-$), hydrogen peroxide (H$_2$O$_2$), and the hydroxyl radical (·OH) [25-29], a highly reactive oxygen species (ROS)[30], as well as nitric oxide (NO·) and the peroxynitrite anion (ONOO$^-$) [31, 32], which are reactive nitrogen species (RNS) [33]. In addition, the indoleamine stimulates the cellular antioxidant defense system increasing mRNA levels and the activities of several important antioxidant enzymes including superoxide dismutase (SOD, which catalyzes the conversion of O$_2^-$ to H$_2$O$_2$) and glutathione peroxidase (GPx) and glutathione reductase (GRd) [34-36]. Catalase (CAT) is also stimulated by melatonin and causes direct breakdown of
H$_2$O$_2$ to O$_2$ and H$_2$O [37, 38]. Moreover, the indoleamine inhibits iNOS, an enzyme involved in NO$^\cdot$ generation [39]. Melatonin also promotes the synthesis of another important antioxidant, glutathione (GSH) [40] and it synergizes with other classic antioxidants to reduce oxidative damage [41]. Finally, melatonin chelates transition metals thereby reducing the formation of the highly toxic ·OH which significantly limits the number of essential molecules that are oxidatively mutilated [42, 43].

Herein, we summarize the protective actions of melatonin against several gastrointestinal diseases, including irritable bowel syndrome, Crohn’s disease, ulcerative colitis, and necrotizing enterocolitis. To the authors’ knowledge, this is the first review related to these subjects.

2. **Irritable bowel syndrome:**

Irritable bowel syndrome (IBS) is a common disorder (prevalence reported between 10-20%) characterized by recurrent abdominal pain or discomfort, in combination with disturbed bowel habits in the absence of identifiable organic cause [44]. IBS is 3-fold more prevalent in women than in men, and in the postmenopausal period this number increases to 6-fold. This may be a consequence of drop in melatonin secretion preceded by the rise in follicle-stimulating hormone (FSH) concentration in postmenopausal women [45, 46]. Its pathophysiology has been associated with abnormal gastrointestinal motor functions, visceral hypersensitivity, psychosocial factors, autonomic dysfunction, mucosal inflammation, and intestinal microbiota imbalance [47, 48]. Moreover, corticotropin releasing factor (CRF) is released during stress, and stimulates colonic motor activity via either central [49, 50] or peripheral CRF receptors [51] resulting in colon hyperkinesis. Depending of the IBS predominant symptoms, there are two clinical types: constipation predominant IBS (IBS-C) and diarrhea-predominant IBS (IBS-D). IBS-D is associated with reduced 5-HT reuptake, while IBS-C is related with lack of 5-HT release [9].
Sleep disorders are also present in 26–55% of IBS patients [52] and are related to rapid eye movement (REM) sleep modifications [53]. In addition, the severity of IBS symptoms is observed to vary with the quality of the previous night’s sleep [54]. It is suggested that sleep disorders are a result of an increase in the activity of the kynurenine pathway (a tryptophan metabolite) (Figure 1) with a reduction in the serotonin/melatonin pathway [55-57]. This theory was considered since some studies reported reduced ratios of kynurenine/tryptophan in IBS patients [58]. One human study observed increased cortisol levels with a reduced melatonin/tryptophan ratio in IBS [58]. The mechanisms responsible for the sleep disorders in IBS patients remain unexplained.

6-Hydroxymelatonin sulphate (6-OHMs) is a hepatic metabolite of melatonin that is excreted in the urine. Urinary levels of 6-OHMs over a 24-hour period correlate well with plasma melatonin levels [59]. Human studies reported increased levels of 6-OHMs in premenopausal and postmenopausal women afflicted with IBS-C or IBS-D [60]. The authors did not observe significant statistical differences between IBS-C symptoms in premenopausal and postmenopausal females and the excretion of 6-OHMs, but a slight increase in levels of metabolite excretion was observed in patients with moderate symptoms. 6-OHMs, concentrations were found to be higher in postmenopausal women affected with IBS-D than in premenopausal females with a large increase in women with exacerbated symptoms. These results support the theory that melatonin levels in IBS women are lowered after menopause [61, 62]. Salivary melatonin levels, which are also well correlated with melatonin plasma concentrations [63], are reduced in IBS patients. The salivary melatonin concentrations increase if melatonin is orally administered [63].

Physicians usually treat IBS with antispasmodics, psychopharmacological treatments, psychotherapy, and newer drugs such as linaclotide, prucalopride, tegaserod, and lubiprostone, but disparate results are observed [64]. Antagonists of the serotonin 5-HT3 receptor are usually used in patients affected with IBS-D, whereas the partial agonist of serotonin 5-HT4 receptor alleviates symptoms of IBS-C [65, 66]. It is suggested that melatonin treatment may play an
important role in the regulation of intestinal motility by inhibiting nicotinic channels in the neurons of the submucosal plexus to regulate the cholinergic transmission and relax muscle contraction through an interaction with small conductance K⁺-channels [12, 67], or by inhibiting the activity of 5-HT and CRF, which are increased in IBS patients [68].

Water avoidance stress generates motility disorders and increases fecal output [69]. In one study it was also observed that melatonin (10 mg/kg i.p.) attenuated the fecal output and reduced the dry weight of the stool. Furthermore, 5-HT serum levels were depressed in melatonin-treated animals suggesting that the modulatory effect may be mediated through the 5-HT pathway. Melatonin also was observed to lower the amplitude of spontaneous contractions of colonic smooth muscle strips as well as ACH-induced and KCl-mediated contractions. This was presumed to be due to an interaction between melatonin and Ca²⁺-activated calmodulin preventing the latter from activating myosin light-chain kinase and inducing a reduced muscle contraction [70]. K⁺-induced contractions are attributed to a Ca²⁺ effect [71]. Melatonin may have reduced the influx of calcium.

Oral melatonin (3 mg) treatment has been also observed to significantly increase colonic transit time of healthy subjects [72]. A similar effect was observed in IBS patients, as in previous studies [63, 68], suggesting a predominant beneficial effect of melatonin in IBS-C patients.

In reference to abdominal pain, it was observed that 3 mg of melatonin given orally for 2 weeks significantly reduced the discomfort with a tendency towards a greater reduction of abdominal distension, stool frequency, and total bowel symptoms. The authors also observed that rectal distension pressure and volume thresholds, which induce the sensations of urgency and pain, were significantly decreased [73]. Similar beneficial effects were obtained in a study in which melatonin improved the quality of life due to the modulation of colonic symptoms including pain severity and frequency, bloating, bowel habit dissatisfaction, and life interference. Extracolonic IBS symptoms such as headache, lethargy, nausea, early satiety, or
urinary disturbances were also improved [74]. Chojnacki et al. [62], in a recent study in postmenopausal women, observed that melatonin therapy significantly reduced pain and abdominal bloating in IBS-C patients. The authors did not find similar results in IBS-D patients or modifications in colonic transit time in either IBS-C or IBS-D subjects. In their study, researchers gave melatonin twice daily (in the morning and in the evening). Thus, they deduced that melatonin administration in a divided dose may be more effective because of melatonin’s short half-life (30–60 min.) [75]. IBS patients usually have symptoms during the day and rarely at night.

3. **Crohn’s disease**

Inflammatory bowel diseases (IBD) include Crohn’s disease (CD) and ulcerative colitis (UC), both chronic inflammatory disorders of the gastrointestinal tract which are characterized by a relapsing and remitting course [76]. In the United States, CD incidence is estimated to be 6-8 per 100,000, with a prevalence of 100-200 per 100,000 [77]. IBD is a result of a miscommunication between the gut microbiota and the intestinal mucosal immune system, resulting in the failure of mucosal homeostasis. The integrity of the epithelial barrier, determined by genetic defects, and the presence of triggering environmental factors are also required to generate chronic inflammation [78]. A genetic polymorphism is not sufficient alone to generate the inflammatory phenotype of IBD [79]. Smoking is observed to be protective for UC and harmful for CD [80]. Moreover, drugs, stress, and dietary habits are also related with IBD pathogenesis [81]. Two recent studies show that melatonin in the gut microbiome may relate to melatonin’s beneficial actions in patients with IBD [82, 83].

Like UC, there exists a relationship between sleep quality and colon disease activity. A poor sleep quality and fatigue are common in clinically active disease compared with inactive disease patients [84, 85]. This effect is more pronounced in those patients with CD compared with UC patients. In addition, it was observed that CD patients with impaired sleep have a two-
fold greater risk of active disease in 6 months, whereas no such relationship has been described in UC patients [86]. Furthermore, symptoms activity is increased in the mornings following a poor night of sleep, and this effect is also more usual in CD patients [87]. However, the relationship between sleep disorders and CD and UC diseases are poorly understood [88]. Figure 2 summarizes these relations.

Melatonin treatment for CD is rare. We found a single article related to the effects of melatonin (3 mg) in a CD patient [89]. The authors observed disease activation after melatonin treatment in a single previously inactive patient. 24 hours after stopping melatonin treatment, the symptoms abated. The authors suggested that melatonin may have activated a number of cytokines (i.e., IL-2 and IL-12) which could have exacerbated the symptoms. This presumption is based on the findings that Th1 and Th17 pathways appear to predominate in the inflamed mucosa of CD patients, whereas Th2 and Th17 factors are abundant in UC [90]. Moreover, it is known that Th1 increases the IFN-γ production in CD [91], and CD patients exhibit elevated lamina propria IL-12 production as compared to controls [92]. Melatonin promotes a Th1-response by increasing IL-12 and IFN-γ levels [93, 94]. The observations of Calvo and co-workers [89] require additional studies in a larger population of CD patients.

JAK kinase family is associated with intracellular signaling, which is initiated by the action of various cytokines. When JAK kinase activity is blocked, this cascade is suspended [95]. Usual treatments such as tofacitinib inhibit JAK1 and JAK3 [96]. A recent study suggested that Neu-P11 (piromelatine, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-pyran-2 carboxamide), a novel melatonin (MT1/MT2) and 5-HT1A/1D receptor agonist [97] protected the cells via activation of the JAK2 survival pathway [98]. A recent meta-analysis determined that a JAK2 rs10758669 polymorphism was significantly associated with CD and UC susceptibility [99]. Moreover, it is known that the activation of JAK2 in IL-R receptor results in the phosphorylation of STAT3 in activated macrophages and dendritic cells [100]. In IBD, JAK2/STAT3 pathway interferes with Th1, Th2, and Th17 cells [101, 102].
SMAD7 and SMAD2 also act as inhibitors of TGF-β1 and were found to be upregulated in CD [103, 104]. New CD treatments such as mongersen inhibits SMAD7 expression thereby restoring TGF-β1 levels; this leads to the suppression of inflammatory cytokine production [104]. Melatonin also inhibits SMAD6 and SMAD7 expression, but facilitates SMAD2 activation [105]. In addition, miR-200b prevents this effect by targeting SMAD2, but its levels are inversely correlated with the TGF-β1 levels in IBD [103]. Recent studies showed that failure of the integrity of the intestinal epithelial barrier may be an early event in the natural history of IBD; this allows for the uncontrolled influx of bacterial products into the lamina propria and the propagation of proinflammatory mucosal responses [106].

TGF-β and IL-6 are also important inducers of Th17 cells producing IL-17 and IL-22. IL-23 interacts with differentiated Th17 cells and causes “stabilization” and/or expansion of Th17 cells [107-109]. In vitro, the addition of melatonin suppresses the polarization of human T helper cells into the Th17 lineage [110]. However, IL-23p19 deficient mice exhibit increased numbers of regulatory T cells (Foxp3+ T cells) [111, 112] and, because of this, CD may develop because of the observed important role of Th1 pathway which causes an 40-fold greater IFN-γ production compare to that induced by IL-17 production [113, 114].

4. Ulcerative colitis:

The incidence of UC is estimated to be 9-12 per 100,000, with a prevalence of 205-240 per 100,000 [77]. Moreover, approximately 20 percent of people with UC have a close relative with IBD [115]. Like CD, the integrity of the epithelial barrier, genetic polymorphisms, and the presence of triggering environmental factors are required to generate the chronic inflammation [78]. Moreover, the incidence of colon cancer is increased in patients with UC, and the risk of colitis-associated colon carcinogenesis (CACC) augments with increased extent and duration of UC [116]. As stated above, Th2 and Th17 pathways are predominant in UC [90]. In addition, IBD-specific changes in the gut microbiota play an important role in UC disease and, because of
that, antibiotics or probiotics may be not effective in some cases [117]. However, probiotics like VSL#3 have high efficacy in preventing the development or recurrence of pouchitis in patients with UC who have undergone ileal-pouch-anal anastomosis [118]. The epithelial barrier also plays an important role in UC and treatment with phosphatidylcholine may restore barrier function and ameliorate intestinal inflammation [119]. Molecules such as tofacitinib, which inhibits JAK1 and JAK3, and several cytokines [78], are effective anti-inflammatory treatments in UC due to inhibition of the differentiation of effector lymphocytes of the Th2 and Th17 types [120]. Elevated IL-4, IL-13, and TGF-β levels are associated with the Th2 pathway [90, 121]. Vedolizumab is a humanized monoclonal antibody with anti-efficacy inflammatory effects on the gut without affecting trafficking of other sites [122]. Etrolizumab also has demonstrated beneficial effects against UC disease [123].

The number of myenteric neurons is reduced in patients affected with UC disease [124]. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a protective factor for different cells and tissues against inflammation and oxidative stress [125]. Nrf2 deficiency is observed to increase oxidative stress and inflammatory processes through an increased production of COX-2, iNOS, IL-1β, IL-6, and TNF-α. Furthermore, in these situations, decreased expression of antioxidant/phase II detoxifying enzymes such as heme oxygenase-1 (HO-1), quinone oxidoreductase (NQO-1), UDP-glucuronosyltransferase 1A1, and GST Mu-1 is observed [126]. It is known that, under oxidative stress conditions, Nrf2 is released from its repressor Kelch-like ECH-associated protein 1 (Keap1) and transforms into its activated form; this results in an activation of antioxidants or detoxifying enzymes [127]. Several studies reported that melatonin regulates Nrf2 expression [128-130]. In rats, Nrf2 expression is reduced in UC [131]. In this study, melatonin upregulated Nrf2 expression thereby ameliorating the histopathological disturbances, including the preservation of myenteric neurons, which play an important role in the regulation of motility and sensitivity of the intestine.

EC proliferation, hydroxyindole-O-methyltransferase (HIOMT) expression (an enzyme involved in melatonin synthesis), and increased urine excretion of 6-OHMs is apparent in the
acute phases of ulcerative proctitis and UC. Consequently, the augmentation of melatonin secretion may have a beneficial effect in anti-inflammatory and defense mechanisms [132]. Melatonin levels are typically lower in active patients than in patients in remission [133].

Sleep deprivation plays an important role in UC by downregulating gene expression. These disturbances are reduced after using melatonin (10 mg/kg i.p.) [134]. In addition, microvascular thrombosis and oxygen free radical-induced injury are known to be important in UC pathogenesis [135, 136]. UC is a Th2 and Th17-like disease associated with increased IL-13 production [137]. IL-17 levels are also elevated in UC due to Th17 activity, but its levels are lower in CD [114]. IL-13, IL-4, and TGF-β levels are also increased in an oxazolone-colitis model; however, IFN-γ levels remain normal [138, 139]. IL-13 is the most important cytokine involved in UC disease. As a result, treatments such as IFN-β are effective in this illness through a reduction in IL-13 levels [121]. Unlike in CD, melatonin may be effective in the treatment of UC via its capacity of attenuate IL-13 levels [140]. In addition, elevated homocysteine (HCY) concentrations stimulate vascular smooth muscle cell proliferation, increase collagen formation and deposition, lead to vascular stenosis and accelerate thrombosis [141, 142]. UC patients have increased plasma and intestinal mucosal levels of HCY [143-145] with reduced levels of melatonin [132]. HCY inhibits GPx levels, decreases NO- bioavailability, and generates H₂O₂ [146]. However, a relationship between melatonin and HCY levels was not observed [132].

Melatonin has been studied as a UC adjuvant treatment. Melatonin benefits against UC syndrome are summarized in table 1. The findings indicate melatonin may reverse the macro- and microscopic lesions. This relates to melatonin’s capacity to limit lipid peroxidation (LPO), myeloperoxidase activity (MPO), reduce inflammatory cytokine levels, and stimulate antioxidant enzymes; these are all oxidative stress markers and are modified during UC [54, 164]. Moreover, STAT-3, an important mediator in IBD, is elevated during UC since this disease is associated with elevated levels of IL-6, which induces STAT3 [165, 166]. NF-κB is important for the inflammatory process; low levels of peroxides induce its activation whereas
some antioxidants reduce its translocation [167, 168]. NF-κB upregulates the expression of TNF-α, IL-1β, iNOS, and COX-2 [169]. Elevated pentraxin-3 (PTX-3) levels, an acute phase protein related to C-reactive protein, is present during inflammatory conditions [170], and a reduction of PTX-3 gene activity results in an inflammatory process in the vascular wall with augmented macrophage accumulation [171]. Moreover, PTX-3 is involved in immune defense in inflamed colon tissue, in particular, in crypt abscess lesions of patients with UC [172]. As summarized in table 1, melatonin reportedly attenuates inflammatory processes thereby alleviating colitis.

Melatonin treatment also significantly enhances expression of Nrf2 and NQO-1, while decreasing matrix metalloproteinase-9 [158]. All these are markers of oxidative stress [173-175]. MMPs mediate cellular infiltration, cytokine activation, cell migration, tissue damage, remodeling and repair [176]. TNF-α stimulates MMP-9 expression while melatonin reduces the levels of this cytokine [147].

From the findings summarized in table 1, one report indicates a detrimental effect of melatonin (1-2 mg/kg) in the evolution of the lesions, levels of TNF-α and MPO activity as well as the hydroxyproline production, an indicator of fibrosis [144]. This latter parameter may be of special interest because fibrosis is a major complication of IBD [177]. These differential effects may be a consequence of diurnal variations of melatonin binding sites during the day [178], with a maximal affinity of the receptors detected in the evening [179]. It is also known that the capacity of melatonin to stimulate gene expression of antioxidant enzymes controls biorhythms [180]. This is consistent with observations in a gastric model of damage that involved ischemia–reperfusion, where melatonin clearly diminished the number and severity of the ulcers in animals treated late in the afternoon while no protection was detected when treatments were applied in the morning [181]. Perhaps the articles with the greatest importance in table 1 are the human studies, which yielded good results when melatonin was used in addition to mesalazine; this suggests a new therapeutic option for this disease.
Melatonin benefits against colitis-associated colon carcinogenesis (CACC) have been uncovered. In a mouse model, melatonin (1 mg/kg) reduced inflammatory markers (MPO, IL-17, IL-6, TNF-α, NF-Kβ, STAT-3, and COX-2), oxidative stress markers (TBARS), autophagy markers (including Beclin-1, LC3B-II/LC3B-I ratio and p62), and DNA damage. Conversely, Nrf2, HO-1, and NQO-1 expression were elevated by melatonin. The benefits of melatonin were also reflected at the histopathological level with a decrease of tumor frequency and dysfunction of calcium-activated calcium channels. The findings indicate that reduced inflammation and oxidative stress due to melatonin intervention in mice inhibits autophagy and prevents CACC malfunctions [182].

5. **Necrotizing enterocolitis**

Necrotizing enterocolitis (NEC) is the most common neonatal gastrointestinal emergency requiring surgical intervention [183, 184]. The prevalence of the disorder is about 7% among infants with a birth weight between 500 and 1500 g, and the estimated rate of death is between 20 and 30% [185]. The pathogenesis of NEC is likely multifactorial, including immature gut function, impaired intestinal barrier, disturbed gastrointestinal motility, and circulatory factors [186]. Platelet-activating factor, intestinal toll-like receptors, TNF-α, interleukins (IL-1β, IL-6, IL-8, IL-10, IL-12), lipopolysaccharide, nitric oxide (NO), and oxygen-derived free radicals may also play pivotal roles in NEC pathogenesis [187-191]. In a preterm infant study [192], the authors measured non-protein bound iron (a marker of potential oxidative stress risk), and markers of free radical damage (advanced oxidation protein products and total hydroperoxides) in the cord blood and observed these were significantly higher in babies with NEC than in healthy infants. Moreover, they reported that toll-like receptor-4 is a crucial component of NEC vulnerability [193].

Human neonates, especially those born prematurely, have an incompletely developed system to detoxify free radicals [194]. Thus, treatments that modulate antioxidative defense and
anti-inflammatory protection including hyperbaric oxygen [195], medical ozone [196], N-acetylcysteine [197], and glutamine alone or in conjunction with arginine [198] have been studied. Melatonin, a molecule that clearly upregulates these systems, ameliorated oxidative stress by reducing MDA levels, an index of lipid peroxidation [199], protein carbonyl content, TNF-α, and IL-1β levels, and stimulated SOD and GPx activities in a rat model of NEC [200]. Melatonin treatment combined with PGE1 [201], a cytoprotective agent in the gastrointestinal system mucosa, had a preventive effect against bacterial invasion and reduced inflammation and tissue injury [2020, 203]. Each provided preventive effects individually but melatonin was more effective in reducing MDA levels and elevating SOD and GPx activities. These results were also reflected at histopathological level. The best results were observed using melatonin and PG concurrently.

6. Conclusions:

IBD and IBS patients exhibit poor sleep quality and reduced levels of melatonin. Moreover, gender and aging are important risk factors for individuals suffering with IBS, with women exhibiting this disease more frequently than men. In IBS-C, melatonin improves life quality and decreases pain. In IBS-D patients the benefits of melatonin are much less apparent possibly because 5-HT receptors play a different role in this pathology. IBD has more similarities to UC, since Th2 and Th17 are involved in both and melatonin has beneficial effects by modulating these pathways. Recent studies also suggest that melatonin may be effective in preventing the progression of colitis-associated colon carcinogenesis due to its capacity to attenuate the induction of autophagy. In contrast, Th1 and Th17 are the major pathways involved in CD, and melatonin increases Th1 activity which induces more injury in the affected tissues. More studies are necessary to identify the potential beneficial effects of melatonin in these illnesses. The potential of melatonin as a treatment for these conditions should be pursued because the usual treatments are not often effective and may have negative secondary effects.
Melatonin may be effective when given in combination with the routinely-used drugs, if for no other reason than, to reduce the side effects of those medications.

7. **Acknowledgements:**

This work was supported by grants from the „Gobierno de Aragón” (Aging and Oxidative Stress Physiology, Grant No. B40) and from the „Instituto de Salud Carlos III” (RD12/0043/0035). Special acknowledgment also is given to the Department of Cellular and Structural Biology of University of Texas Health Science Center at San Antonio for hosting E.E.Z. during the preparation of this review.
8. References:


[58] M.M. Heitkemper, C.J. Han, M.E. Jarrett, H. Gu, D. Djukovic, R.J. Shulman, D. Raftery, W.A. Henderson, K.C. Cain, Serum Tryptophan Metabolite Levels During Sleep


[128] I. Crespo, B.S. Miguel, A. Laliena, M. Alvarez, J.M. Culebras, J. González-Gallego, M.J. Tuñón, Melatonin prevents the decreased activity of antioxidant enzymes and


regulates goblet cell development and is required for necrotizing enterocolitis in mice, Gastroenterology 143 (2012) 708-718.


Figure 1: Kynurine and melatonin pathways. It is suggested that sleep disorders generated in patients affected of irritable bowel syndrome are a result of an increase in the activity of the kynurenine pathway with a reduction in the serotonin/melatonin pathway.

Figure 2: Sleep disruption increases ulcerative colitis and Crohn’s disease disturbs. However, these alterations may also induce sleep disruption, generating a loop not well understood yet.
MEL ameliorated the disruption of the colonic architecture, reduced MPO activity, MDA levels, appearance of nitrotyrosine, PARS immunoreactivity, ICAM-1 expression, and the expression of P-selectin. Staining degree of COX-2 and iNOS were also reduced.

MEL, in a dose-dependent manner, inhibit iNOS and COX-2 expression, decreased NO- and PGE2; levels,

MEL treatment, in a dose-dependent manner, reduced macro/microscopic lesions, TNF-α, and ICAM-1 protein expression, and NF-κB activation. MEL 10 mg/kg obtained similar results to 5-aminosalicylic acid (5-ASA) group.

MEL attenuates macro/microscopic lesions, reduced the degree of the expression of JNK, attenuates TNF-α and IL-1β levels, and NF-κB, Bcl-2 and Bax expression.

In a dose-dependent manner, MEL reduced macroscopic lesions, increased GSH levels, and decreased MPO activity.

MEL treatment reduced macro/microscopic lesions, and maintain body and colon weight.

MEL reduced UC activity, tumor multiplicity, and progression of colon carcinogenesis, and GSH levels.

DSS–induced colitis in rats 15 mg/kg i.p. MEL attenuates macro/microscopic lesions, reduced the degree of the expression of JNK, attenuates TNF-α and IL-1β levels, and NF-κB, Bcl-2 and Bax expression.

AA-induced colitis in rats 5 mg/kg and 10 mg/kg i.p. or i.c. In a dose-dependent manner, MEL reduced macroscopic lesions, increased GSH levels, and decreased MPO activity.

DNBS–induced colitis in rats 15 mg/kg i.p. MEL treatment reduced macro/microscopic lesions, MDA levels and TNF-α level. MEL also reduced MMP-2 and MMP-9 activities after DNBS-induced colitis.

AA-produced macro/microscopic lesions, increased MPO activity, and increased MDA, IL-1β, IL-6, and iNOS levels. MEL attenuates significant statistical all these disturbances. GSH and SOD activity were also increased.

AA produced macro/microscopic lesions, increased MPO activity, and increased MDA, IL-1β, IL-6, and iNOS levels. MEL attenuates significant statistical all these disturbances. GSH and SOD activity were also increased.

MEL reduced UC activity, c-reactive protein levels, and attenuates the decreased hemoglobin concentration in blood observed in non-melanotin treatment group.

Table 1: Studies related to melatonin’s benefits in ulcerative colitis (UC). MEL, Melatonin, MPO; myeloperoxidase, MDA; malondialdehyde, iNOS; inducible nitric oxide synthase, NO-; nitric oxide, PGE2; prostaglandin, E2; GSH, glutathione, MMP, matrix metalloproteinase; SOD, superoxide dismutase; PTX-3: pentraxin-3.
Figure 1
Figure 2
Graphical abstract